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Summary
Background.  —  Previous  studies  have  investigated  the  relationship  between  CYP2C19  polymor-
phism and  clinical  prognosis  in  coronary  artery  disease  patients  treated  with  clopidogrel,  but
the results  were  inconsistent.
Aims.  —  To  assess  the  impact  of  CYP2C19  polymorphism  on  the  risk  of  adverse  clinical  events
by performing  a  meta-analysis  of  relevant  studies  in  the  last  few  years.
Methods.  —  Prospective  cohort  studies  or  post-hoc  analyses  of  randomized  controlled  trials
were identiﬁed  from  the  databases  of  PubMed/Medline,  EMBASE  and  the  Cochrane  Library.  End-
points were  fatal  or  non-fatal  myocardial  infarction,  cardiovascular  or  all-cause  death,  deﬁnite
or probable  stent  thrombosis,  target  vessel  revascularization,  target  lesion  revascularization,
urgent revascularization,  ischaemic  stroke  and  bleeding.  Pooled  effects  were  measured  by  odds
ratios (ORs)  with  95%  conﬁdence  intervals  (CIs).
Abbreviations: ACS, Acute coronary syndrome; CAD, Coronary artery disease; CI, Conﬁdence interval; CYP, Cytochrome P450; MI,
Myocardial infarction; OR, Odds ratio; PCI, Percutaneous coronary intervention; PCR, Polymerase chain reaction; ST, Stent thrombosis; TLR,
Target lesion revascularization; TVR, Target vessel revascularization.
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Results.  —  A  total  of  21  studies  involving  23,035  patients  were  included.  Compared  with  non-
carriers of  the  CYP2C19  variant  allele,  the  carriers  were  found  to  have  an  increased  risk  of
adverse clinical  events  (OR  1.50,  95%  CI  1.21—1.87;  P  =  0.0003),  myocardial  infarction  (OR  1.62,
95% CI  1.35—1.95;  P  <  0.00001),  stent  thrombosis  (OR  2.08,  95%  CI  1.67—2.60;  P  <  0.00001),
ischaemic  stroke  (OR  2.14,  95%  CI  1.36—3.38;  P  =  0.001)  and  repeat  revascularization  (OR  1.35,
95% CI  1.10—1.66;  P  =  0.004),  but  not  of  mortality  (P  =  0.500)  and  bleeding  events  (P  =  0.930).
Conclusion.  —  CYP2C19  polymorphism  is  signiﬁcantly  associated  with  risk  of  adverse  clinical
events in  clopidogrel-treated  patients.
© 2013  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé
Justiﬁcation.  —  Des  études  ont  été  réalisées  établissant  le  lien  entre  polymorphisme  du
cytochrome  CYP2C19  et  le  pronostic  des  patients  coronariens  traités  par  clopidogrel,  mais  les
résultats sont  divergents.
Objectifs.  —  Évaluer  l’impact  du  polymorphisme  CYP2C19  sur  le  risque  d’évènements  indésir-
ables en  réalisant  un  méta-analyse  des  études  publiées  récemment.
Méthode.  —  Les  études  de  cohortes  prospectives  ou  les  analyses  post-hoc  des  essais  randomisés
ont été  identiﬁées  à  l’aide  d’une  analyse  des  bases  de  données  PubMed,  Medline,  Embase  et  la
collaboration  Cochrane.  Le  critère  de  jugement  était  la  survenue  d’un  infarctus  du  myocarde
fatal ou  non,  le  décès  cardiovasculaire  ou  toute  cause,  la  thrombose  de  stent  probable  ou  cer-
taine, la  revascularisation  des  vaisseaux  cible,  la  revascularisation  de  la  lésion  cible,  l’indication
à une  revascularisation  urgente,  la  survenue  d’un  accident  ischémique  cérébral  et  le  saigne-
ment. Les  effets  ont  été  évalués  par  la  détermination  des  odds  ratio  et  des  intervalles  de
conﬁance  à  95  %.
Résultats.  —  Un  total  de  21  études  incluant  23  035  patients  ont  été  inclues  dans  l’analyse.  En
comparaison  des  patients  non  porteurs  de  l’allèle  variant  CYP2C19,  les  porteurs  avaient  un
risque accru  d’évènements  cliniques  (odd  ratio  1,50,  IC  95  %  1,21—1,87,  p  =  0,0003),  le  risque
d’infarctus  du  myocarde  (odd  ratio  1,62,  IC  95  %  1,35—1,95,  p  <  0,00001),  de  thrombose  de
stent (odd  ratio  2,08,  IC  95  %  1,67—2,60,  p  <  0,00001),  d’accident  ischémique  cérébral  (odd
ratio 2,14,  IC  95  %  1,36—3,38,  p  =  0,001)  et  l’indication  de  revascularisation  répétée  (odd  ratio
1,35, IC  95  %  1,10—1,66,  p  =  0,004).  Il  n’y  avait  pas  d’augmentation  signiﬁcative  du  risque  de
décès (p  =  0,500)  et  de  saignement  (p  =  0,930).
Conclusion.  — Le  polymorphisme  du  cytochrome  CYP2C19  est  signiﬁcative  associé  avec  un  risque
d’évènements  clinique,  décès  et  infarctus  du  myocarde,  chez  les  patients  traités  par  clopido-
grel.
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s  an  irreversible  inhibitor  of  the  adenosine  diphosphate
2Y12  receptor,  clopidogrel  plays  an  important  role  in  the
revention  of  stent  thrombosis  (ST)  in  coronary  artery
isease  (CAD)  patients  undergoing  percutaneous  coronary
ntervention  (PCI)  [1,2].  However,  about  4—30%  of  the
atients  treated  with  clopidogrel  display  no  or  a  low
nti-platelet  response  [3—5].  This  phenomenon  is  called  clo-
idogrel  resistance  or  clopidogrel  non-responsiveness  [6].
ccording  to  previous  studies  [7,8],  these  patients  may  have
n  increased  risk  of  ischaemic  cardiovascular  events.
The  mechanisms  of  this  phenomenon  are  not  fully  elu-
idated.  We  know  that  clopidogrel  is  an  inactive  prodrug
hat  requires  oxidation  by  the  hepatic  cytochrome  P450
CYP)  system  to  generate  an  active  metabolite.  As  a
esult,  mutations  in  the  genes  for  these  CYP  enzymes  may
ffect  clopidogrel  responsiveness  [6,9].  Among  these  genes,
YP2C19  is  of  great  concern.  The  CYP2C19*17  allele,  which
ill  not  be  discussed  in  this  article,  may  enhance  platelet
esponse  to  clopidogrel  in  acute  coronary  syndrome  (ACS)
atients  [10].  On  the  other  hand,  loss-of-function  alleles,
T
t
is  droits  réservés.
uch  as  CYP2C19*2  and  CYP2C19*3,  which  we  will  discuss  in
his  article,  are  responsible  for  reduced  activation  of  clo-
idogrel  and  increase  the  risk  of  recurrent  cardiovascular
vents  in  CAD  patients  [11—13].  Recently,  to  evaluate  the
ssociation  between  CYP2C19  polymorphism  and  adverse
ardiovascular  events  in  CAD  patients  treated  with  clo-
idogrel,  more  and  more  studies  have  been  performed
10,14—22].  However,  the  results  have  not  been  consistent.
hus,  we  performed  a  meta-analysis  of  cohort  studies  or
ost-hoc  analyses  of  randomized  controlled  trials  to  inves-
igate  the  effects  of  CYP2C19  polymorphism,  especially
YP2C19*2,  on  adverse  clinical  events  in  clopidogrel-treated
atients.
ethods
earch methods and selection criteriawo  reviewers  (CJ  and  HD)  independently  performed  elec-
ronic  searches  for  CYP2C19  polymorphism  and  clopidogrel
n  PubMed/Medline,  EMBASE  and  the  Cochrane  Library,
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selected  accordingly  (Fig.  2).  The  results  of  twenty
comparisons  showed  that  carriers  (n  =  6868)  of  the
CYP2C19  variant  allele  had  a  higher  risk  of  adverseCytochrome  CYP2C19  polymorphism  and  adverse  events  
with  the  following  search  strategy  ‘‘(clopidogrel)  and  (P450
2C19  OR  CYP2C19)  and  (coronary  heart  disease  or  coronary
artery  disease)’’,  from  their  inception  through  to  February
2013.  The  language  was  restricted  to  English  or  Chinese.
The  selection  criteria  for  eligible  studies  were  as  follows:
study  type  (prospective  cohort  studies  or  post-hoc  analy-
ses  of  randomized  controlled  trials);  participants  (coronary
artery  disease  patients  treated  with  clopidogrel);  deﬁnite
clinical  endpoints  (fatal  or  non-fatal  myocardial  infarc-
tion  [MI],  cardiovascular  death,  all-cause  death,  deﬁnite  or
probable  stent  thrombosis  [ST],  target  lesion  revasculari-
zation  [TLR],  target  vessel  revascularization  [TVR],  urgent
revascularization,  ischaemic  stroke  and  bleeding);  genotyp-
ing  (loss-of-function  genotypes  [CYP2C19*2—*8],  especially
CYP2C19*2,  should  be  detected  in  the  studies);  comparison
(comparison  of  the  outcomes  between  mutant  gene  carriers
and  non-carriers).  Meeting  abstracts,  case  reports,  editori-
als  and  reviews  were  excluded.
Data extraction and quality assessment
Data  extraction  was  completed  by  two  investigators  (LM  and
LC),  independently.  Study  type,  country,  population  charac-
teristics,  number  of  patients,  mean  age,  clopidogrel  dose,
combination  of  aspirin,  genotyping  method,  genotype  dis-
tribution,  length  of  follow-up,  study  endpoints,  number  of
each  event,  adjustment  for  confounding  factors  and  conclu-
sions  were  collected.  Any  occurrence  of  events,  such  as  fatal
or  non-fatal  MI,  cardiovascular  or  all-cause  death,  deﬁnite  or
probable  ST,  TVR,  TLR,  urgent  revascularization,  ischaemic
stroke  or  bleeding,  was  considered  to  be  an  adverse  clinical
outcome  in  our  meta-analysis.  Disagreements  were  resolved
by  discussion  between  the  two  investigators.
The  Newcastle-Ottawa  quality  assessment  scale  was  used
to  assess  the  quality  of  the  included  studies  [23,24].  This
scale  consists  of  three  categories:  selection  (representative-
ness  of  the  exposed  cohort,  selection  of  the  non-exposed
cohort,  ascertainment  of  exposure  and  demonstration  that
the  outcome  of  interest  was  not  present  at  the  start  of
the  study);  comparability  (comparability  of  cohorts  on  the
basis  of  the  design  or  analysis);  and  outcome  (assessment  of
outcome,  follow-up  long  enough  for  outcomes  to  occur,  ade-
quacy  of  follow-up  of  the  cohorts).  The  highest  score  that  a
study  can  be  awarded  is  nine.
Statistical analysis
In  this  article,  the  P  value  was  set  at  0.10  for  heterogeneity
tests  and  at  0.05  for  others.  All  the  P  values  were  two-
tailed.  Cochran’s  Q  test  and  I2 were  used  to  investigate
heterogeneity;  the  funnel  plot  analysis  was  used  to  evaluate
publication  bias.  I2 values  >  25%,  >  50%  and  >  75%  were  con-
sidered  as  evidence  of  low,  moderate  and  severe  statistical
heterogeneity,  respectively.  If  I2 was  >  50%  or  P  was  <  0.10,
a  random-effect  model  was  chosen.  Accordingly,  we  ran  a
ﬁxed-effect  model  if  I2 was  <  50%  or  P  was  >  0.10.  Crude  odds
ratios  (ORs)  with  95%  conﬁdence  intervals  (CIs)  were  used  to
assess  the  strength  of  the  association  between  cytochrome
CYP2C19  polymorphism  and  clinical  prognosis.  All  statistical
tests  were  performed  with  Review  Manager  5.1  for  Windows,
available  from  the  Cochrane  Collaboration. F519
esults
tudy selection
 total  of  421  relevant  publications  were  evaluated
nitially.  Finally,  21  studies  met  the  inclusion  criteria
13,17—22,25—38]. The  study  selection  ﬂow  diagram  is
hown  in  Fig.  1. In  total,  23,035  patients  were  included  in
his  meta-analysis.  Among  these  patients,  7670  were  car-
iers  of  the  CYP2C19  variant  allele  (mostly  CYP2C19*2);
he  other  15,365  patients  were  non-carriers.  Eight  stud-
es  [13,18—20,22,25—27]  were  from  Asia  and  thirteen
15,21,28—38]  were  from  Europe  or  the  USA.  The  load-
ng  dose  of  clopidogrel  was  300  mg  or  600  mg  in  18  studies
13,15,18—20,22,25—27,29,31—38]  and  all  the  participants
ere  given  a  maintenance  dose  of  75  mg/day.  The  TaqMan
Applied  Biosystems,  Foster  City,  CA,  USA)  polymerase  chain
eaction  (PCR)  was  chosen  as  the  genotyping  method  in
1.9%  of  the  studies.  The  length  of  follow-up  ranged  from
 month  to  4  years.  Study  characteristics  are  reported  in
able  1.
ssociation between CYP2C19 polymorphism
nd adverse clinical events
eterogeneity  test  results  indicated  statistical  hetero-
eneity  among  the  included  studies  [13,15,18—22,26—38]
I2 =  67%,  P  <  0.00001)  and  a  random-effect  model  wasigure 1. Flow diagram of the systematic review process.
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Table  1  Main  characteristics  of  all  the  studies  included  in  the  meta-analysis.
Study  Year  Country  Study
population
Age
(years)
Carriers/non-
carriers
(n/n)
Clopidogrel
dose
(LD→MD)
Follow-up
(months)
Endpoints  Genotyping
method
Genetic
variant
NOS
Nishio  et  al.  [18]  2012  Japan  PCI  69.8  100/60  300  mg  →
75 mg/day
21.5  Death,  ST,  MI,
TLR
TaqMan  PCR  *2,  *3  9
Peng  et  al.  [20]  2013  China  CAD  64.9  271/235  300  mg  →
75 mg/day
12  Non-fatal  MI,
death,  stroke,
revascularization
TaqMan  PCR  *2  9
Trenk  et  al.  [37]  2008  Germany  Elective  PCI  66.3  245/552  600  mg  →
75 mg/day
12  RPA,  death,
non-fatal  MI
TaqMan  PCR  *2  9
Harmsze  et  al.  [30]  2010  Netherlands  PCI  62.7  193/403  NA  12  ST  PCR  *2,  *3  8
Tang  et  al.  [22]  2012  China  PCI  58.9  384/286  300  mg  →
75 mg/day
12  Cardiovascular
death,  MI,  TVR,
ST
LDR  *2,  *3,
*17
9
Bouman  et  al.  [15]  2011  Germany  CAD  +  PCI  61.2  37/75  600  mg  →
75 mg/day
18  ST  TaqMan  PCR  *2  9
Sawada  et  al.  [26]  2011  Japan  PCI  69.6  42/58  300  mg  →
75 mg/day
18.2  ST,  death,  MI,
TVR
TaqMan  PCR  *2  7
Pare  et  al.  [33]  2010  Canada  NSTE-ACS  63.8  650/1880  300  mg  →
75 mg/day
12  Death,  non-fatal
MI,  stroke
TaqMan  PCR  *2,  *3  9
Yamamoto  et  al.  [13]  2010  Japan  Stable  CHD  68.6  62/36  300  mg  →
75 mg/day
12  Death,  non-fatal
MI,  ischaemic
stroke
PCR  *2,  *3  8
Giusti  et  al.  [29]  2009  Italy  ACS  +  PCI  NA  247/525  600  mg  →
75 mg/day
6  ST  PCR  *2  9
Collet  et  al.  [28]  2009  France  MI  40.1  73/186  NA  →
75  mg/day
>  48  Death,  non-fatal
MI,  urgent
revascularization
TaqMan  PCR  *2  9
Shuldiner  et  al.  [34]  2009  America  Elective  PCI  65.1  67/158  600  or
300  mg  →
75 mg/day
12  MI,  stroke,  ST,
death
SNPlexa *2  9
Wallentin  et  al.  [38]  2010  America,
Europe
ACS  62.5  1388/3516  600  or
300  mg  →
75 mg/day
12  Cardiovascular
death,  MI,  stroke
TaqMan  PCR  *2∼*8,
*17
8
Tiroch  et  al.  [36]  2010  Germany  Acute  MI  64.8  248/680  600  mg  →
75 mg/day
12  TLR,  death,  MI  TaqMan  PCR  *2,  *17  9
Mega  et  al.  [32]  2009  America,
Europe
ACS  +  PCI  60.1  395/1064  300  mg  →
75 mg/day
15  Cardiovascular
death,  MI,  stroke
PCR  *2  9
Sibbing  et  al.  [35]  2009  Germany  CAD  +  PCI  66.5  680/1805  600  mg  →
75 mg/day
1  ST  TaqMan  PCR  *2  8
Simon  et  al.  [21]  2009  France  Acute  MI  66.2  617/1561  300—900  mg  →
75  mg/day
12  Death,  non-fatal
MI,  stroke
SNPlexa *2∼*5,
*17
8
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Table  1  (Continued)
Study  Year Country  Study
population
Age
(years)
Carriers/non-
carriers
(n/n)
Clopidogrel
dose
(LD→MD)
Follow-up
(months)
Endpoints  Genotyping
method
Genetic
variant
NOS
Malek  et  al.
[31]
2008  Poland ACS  +  PCI 60.0 21/84 300  or
600  mg  →
75 mg/day
12 Death,  MI TaqMan  PCR *2  8
Tang  et  al.
[27]
2011  China  CHD  +  PCI 58.0 137/130 300  mg  →
75 mg/day
12 Death,  angina
recurrence,  MI,
urgent  revascula-
rization,
ST
MALDI-
TOF  MS
*2  9
Luo  et  al.
[25]
2011  China  CHD  +  PCI  70.8  802/936  300  mg  →
75 mg/day
6 ST,  death,  MI,
ischaemic  stroke,
bleeding
TaqMan  PCR  *2  9
Oh  et  al.
[19]
2011  Korea  PCI  60.8  1011/1135  300  or
600  mg  →
75 mg/day
12 Death,  non-fatal
MI,  ST,  TVR,  TLR
TaqMan  PCR  *2  9
ACS: acute coronary syndrome; CAD/CHD: coronary artery disease; LD: loading dose; LDR: ligase detection reaction; NSTE: non-ST-segment elevation; MALDI-TOF MS: matrix-assisted laser
desorption/ionization-time of ﬂight mass spectrometry; MD: maintenance dose; MI: myocardial infarction; NA: not available; NOS: Newcastle-Ottawa scale; PCI: percutaneous coronary
intervention; PCR: polymerase chain reaction; RPA: residual platelet aggregation; ST: stent thrombosis; TLR: target lesion revascularization TVR: target vessel revascularization.
a Applied Biosystems, Foster City, CA, USA.
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Figure 2. Forest plot of odds ratios for the occurrence of adverse clinical events (the composite of fatal or non-fatal myocardial infarction,
cardiovascular or all-cause death, deﬁnite or probable stent thrombosis, target lesion revascularization, target vessel revascularization,
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Prgent revascularization, ischaemic stroke and bleeding), according
linical  events  than  the  14,429  non-carriers  (OR  1.50,
5%  CI  1.21—1.87,  Z  =  3.63;  P  =  0.0003).  In  the  subgroup
nalysis,  we  divided  the  studies  into  two  subgroups
ccording  to  ethnicity.  The  Asian  and  Caucasian  sub-
roups  consisted  of  seven  studies  [13,18—20,22,26,27]
nd  13  studies  [15,21,28—38],  respectively.  In  contrast
o  the  Caucasian  group  (I2 =  68%;  P  =  0.0002),  no  statisti-
al  heterogeneity  was  found  in  the  Asian  group  (I2 =  0%;
 =  0.61);  the  results  were  also  different  (OR  1.27,  95%  CI
.02—1.58  vs  OR  2.75,  95%  CI  1.88—4.01,  respectively).
hese  data  are  shown  in  detail  in  Supplementary  data,
igs.  A  and  B.
ssociation between CYP2C19 polymorphism
nd the risk of myocardial infarctions  shown  in  Fig.  3,  11  studies  [13,18,19,25—28,31,32,35,36]
nvolving  9745  participants  were  included  here  to  assess
he  association  between  CYP2C19  polymorphism  and  the
T
c
t
PYP2C19 gene variant.
isk  of  MI.  As  no  statistical  heterogeneity  was  found  in
his  analysis  (P  =  0.13,  I2 =  33%),  we  selected  a  ﬁxed-effect
odel.  The  results  showed  that  patients  who  carried  a  loss-
f-function  allele,  mainly  CYP2C19*2,  had  a  higher  risk  of
I  during  follow-up  (OR  1.62,  95%  CI  1.35—1.95,  Z  =  5.15;
 <  0.00001).
ssociation between CYP2C19 polymorphism
nd the risk of stent thrombosis
ig.  4  shows  the  result  of  the  meta-analysis  of  the  asso-
iation  between  CYP2C19  polymorphism  and  the  risk  of
T.  Thirteen  studies  [15,18,19,25,27—32,35,36,38]  involv-
ng  14,261  patients  were  included  in  this  analysis.  There
as  no  evidence  of  signiﬁcant  heterogeneity  (I2 = 28%;
 =  0.16)  and  data  were  assessed  by  the  ﬁxed-effect  model.
here  was  a  two-fold  increase  in  the  rate  of  ST  in
arriers  who  underwent  stent  implantation  compared  to
he  non-carriers  (OR  2.08,  95%  CI  1.67—2.60,  Z  = 6.51;
 <  0.00001).
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Figure 3. Forest plot of odds ratios for the occurrence of myocardial infarction, according to CYP2C19 gene variant.
Figure 4. Forest plot of odds ratios for the occurrence of stent thrombosis, according to CYP2C19 gene variant.
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Table  2  Results  of  meta-analysis  of  the  occurrence  of  other  adverse  clinical  events,  according  to  CYP2C19  gene  variant.
Comparisons  Carriers/non-carriers  (n/n)  I2 (%)  Analysis  model  OR  95%  CI  P
Mortality  4089/6934  36  Fixed  1.12  0.81—1.55  0.500
Ischaemic  stroke  2187/4521  33  Fixed  2.14  1.36—3.38  0.001
Bleeding  events  3609/7669  0  Fixed  1.01  0.85—1.19  0.930
Repeat  revascularization  1882/2484  49  Fixed  1.35  1.10—1.66  0.004
CI: conﬁdence interval; OR: odds ratio.
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ﬁssociation between CYP2C19 polymorphism
nd the risk of mortality, ischaemic stroke,
epeat revascularization and bleeding events
verall,  mortalities  (cardiovascular  death  or
ll-cause  death)  were  reported  in  13  articles
13,18—20,25—29,31,32,35,36].  The  numbers  of  studies  that
ecorded  occurrences  of  strokes,  repeat  revascularizations
nd  bleeding  events  were  ﬁve,  seven  and  six,  respectively.
ata  are  shown  in  detail  in  (Supplementary  data,  Figs.
—F).  Table  2  shows  the  results  of  the  meta-analysis  of
hese  adverse  clinical  events.  Carriers  had  a  higher  risk
f  ischaemic  stroke  (OR  2.14,  95%  CI  1.36—3.38,  Z  =  3.27;
 =  0.001)  and  repeat  revascularization  (OR  1.35,  95%  CI
.10—1.66,  Z  =  2.87;  P  =  0.004)  than  non-carriers.  However,
o  statistically  signiﬁcant  difference  was  found  between
he  two  groups  in  terms  of  risk  of  mortality  or  bleeding
vents.
iscussion
he  combination  of  aspirin  and  clopidogrel  is  the  mainstay
nti-platelet  strategy  for  preventing  ischaemic  events  after
CI  [39].  Clopidogrel  is  an  inactive  prodrug  that  requires
xidation  by  the  CYP  system.  About  50%  of  the  clopidogrel
aken  by  patients  is  absorbed  in  the  gastrointestinal  tract.
nly  15%  of  this  clopidogrel  is  metabolized  and  activated  in
he  liver.  The  thiophene  ring  of  clopidogrel  is  oxidized  to
orm  an  intermediate  metabolite  (2-oxo-clopidogrel).  In  the
urther  oxidizing  process,  2-oxo-clopidogrel  opens  the  thio-
hene  ring  and  breaks  up  into  a  carboxyl  and  thiol  group.  The
eactive  thiol  group  forms  a  disulphide  bridge  between  one
r  more  cysteine  residues  of  the  P2Y12  receptor  and  irre-
ersibly  blockades  the  platelet  [6].  Despite  the  widespread
se  of  clopidogrel  and  aspirin,  the  incidence  rate  of  throm-
otic  stent  occlusion  after  coronary  stenting  has  been  shown
o  be  as  high  as  4.7%  [4].  Recently,  gene  polymorphism  of
ytochrome  CYP2C19  was  reported  to  be  responsible  for  the
igh  risk  of  adverse  clinical  outcomes  in  patients  undergoing
tent  implantation  [29,40].  The  CYP2C19  gene  polymor-
hism  is  not  uncommon.  About  30%  of  Caucasians  and  55%  of
sians  have  one  or  more  loss-of-function  allele  of  CYP2C19.
Using  the  Newcastle-Ottawa  quality  assessment  scale,e  selected  the  potential  articles  strictly.  All  the  included
tudies  had  a  score  of  seven  or  more,  which  indicates
he  high  quality  of  the  evidence  in  this  meta-analysis.
ccording  to  the  funnel  plot  shown  in  Supplementary
p
i
m
pata,  Fig.  G,  the  publication  bias  was  acceptable.  Some
tudies  reported  major  adverse  cardiovascular  events
28,31,32,35,37,38,41], but  others  did  not  [15,25,30].
inally,  because  of  the  different  endpoints  in  the  included
tudies,  we  deﬁned  these  outcomes  as  ‘‘adverse  clinical
vents’’  in  this  meta-analysis.
Using  data  from  all  21  studies  (7670  carriers  and
5,365  non-carriers),  we  found  that  CYP2C19  polymor-
hism  was  signiﬁcantly  associated  with  an  increased
isk  of  adverse  clinical  events  among  clopidogrel-treated
atients.  However,  there  was  a  statistical  heterogene-
ty  among  the  20  included  studies  [13,15,18—22,26—38]
I2 =  67%;  P  <  0.00001).  As  a  result,  we  chose  a  random-effect
odel.  In  the  subgroup  analysis,  we  found  that  carriers
n  Asia  were  more  prone  to  adverse  clinical  events  than
atients  in  Western  countries.  In  comparison  with  the  Cau-
asian  group,  no  statistical  heterogeneity  was  found  in  the
sian  group.  In  our  opinion,  ethnic  diversity  could  be  respon-
ible  for  the  heterogeneity  in  this  meta-analysis.  In  addition,
he  difference  in  endpoints,  follow-up  periods  and  disease
everities  in  the  studies  also  contributed  to  the  heterogene-
ty.  Furthermore,  no  statistical  heterogeneity  was  found  in
he  analysis  of  MI  and  ST.  Our  results  suggested  a  two-fold
ncrease  in  the  rate  of  ST  and  a  1.64-fold  increase  in  the
ate  of  MI  in  carriers  compared  with  non-carriers  during
he  follow-up  period.  Similar  ﬁndings  were  observed  in  the
eta-analyses  performed  by  Jang  et  al.  [41]  and  Zabalza
t  al.  [42].
The  relationships  between  CYP2C19  polymorphism  and
ortality,  ischaemic  stroke,  repeat  revascularization  and
leeding  events  were  also  assessed  in  our  study.  Although
imilar  ﬁndings  were  reported  by  Jin  et  al.  [43],  previous
ystematic  reviews  [41—44]  did  not  analyse  the  associa-
ion  between  CYP2C19  polymorphism  and  the  risk  of  repeat
evascularization.  Here,  we  also  found  that  CYP2C19  vari-
nt  gene  carriers  were  more  likely  to  experience  repeat
evascularization  and  ischaemic  stroke.
Recently,  the  United  States  Food  and  Drug  Administra-
ion  added  a warning  to  clopidogrel  stating  that  patients
ith  decreased  CYP2C19  function  because  genetic  poly-
orphisms  may  metabolize  clopidogrel  poorly  and  have
igher  rates  of  cardiovascular  events  after  ACS  and  PCI  than
atients  with  normal  CYP2C19  function  [45]. Our  ﬁndings
resent  support  the  evidence  for  this  warning.  Given  these
ndings,  we  think  that  pharmacogenomic  testing  for  CAD
atients  who  need  long-term  clopidogrel  therapy,  especially
n  Asian  populations,  will  be  necessary  and  helpful.  By  this
eans,  we  will  then  be  able  to  predict  their  response  to  clo-
idogrel  and  make  individualized  treatment  decisions.  We
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believe  that  this  kind  of  genetic  guided  therapy  is  promis-
ing  and  may  play  a  key  role  in  our  clinical  practice  in  the
foreseeable  future.  It  just  goes  to  show  that  P4  (predictive,
preventive,  personalized,  participatory)  medicine  is  coming
[46].
If  patients  are  CYP2C19  variant  gene  carriers  and  display
low  or  no  anti-platelet  response,  other  drugs  should  be  taken
into  consideration  [47].  The  Food  and  Drug  Administration
has  approved  two  additional  P2Y12  receptor  inhibitors  for
use  in  patients  with  ACS.  Prasugrel  and  ticagrelor  were  more
effective  than  clopidogrel  at  reducing  clinical  events,  but
at  the  expense  of  an  increased  risk  of  bleeding  [48]. Pra-
sugrel  is  a  prodrug  that  requires  conversion  to  its  active
metabolite.  At  least  two  observational  studies  have  demon-
strated  no  signiﬁcant  decrease  in  plasma  concentrations  of
prasugrel  active  metabolite  or  platelet  inhibition  activity  in
carriers  of  at  least  one  loss-of-function  allele  of  the  CYP2C19
isoenzyme  [49,50].  On  the  other  hand,  ticagrelor,  the  latest
FDA-approved  P2Y12  receptor  inhibitor,  is  a  reversible  direct
acting  oral  antagonist  of  the  P2Y12  receptor  that  does  not
require  transformation  to  an  active  metabolite  [51].  Clinical
use  of  genotyping  and  platelet  function  testing  for  prasug-
rel  and  ticagrelor  is  not  rigorously  established  but  it  is  less
likely  to  be  necessary  given  the  lesser  degree  of  variation  in
response  than  clopidogrel.  According  to  the  evidence  [51],
prasugrel  should  not  be  prescribed  to  patients  with  a  history
of  transient  ischaemic  attack  or  stroke,  or  with  active  patho-
logical  bleeding  for  bleeding  prevention.  To  reduce  the  risk
of  gastrointestinal  hemorrhage,  co-administration  of  proton
pump  inhibitors  has  also  been  recommended  for  patients
who  are  at  a  higher  risk  of  bleeding  events  [52].
Study limitations
Some  limitations  should  be  considered.  First,  only  publica-
tions  in  English  and  Chinese  were  considered  in  our  search
process;  some  studies  in  other  languages  were  inevitably
lost.  Second,  the  predetermined  endpoints  in  the  included
studies  were  different.  We  could  only  extract  information
in  part  from  these  studies.  Furthermore,  the  genotyping
methods  were  not  the  same  in  the  included  studies.  As
a  result,  there  is  a  detection  bias  to  a  certain  degree.
Besides,  some  included  studies  did  not  have  adequate
power  to  detect  possible  risk  for  CYP2C19  polymorphism
because  of  their  small  sample  sizes.  Lastly,  the  length
of  follow-up  varied  from  1  month  to  4  years  across  the
included  studies.  There  is  also  an  attrition  bias  to  a  cer-
tain  degree.  However,  Peng  et  al.  [20]  recently  reported
that  the  adverse  impact  of  the  CYP2C19*2  gene  muta-
tion  was  signiﬁcantly  reduced  after  1  year  of  discharge.  Is
CYP2C19  polymorphism  responsible  for  long-term  progno-
sis  in  clopidogrel-treated  patients?  More  studies  are  still
needed.
ConclusionsIn  conclusion,  the  synthesis  of  available  evidence  indicates
that  CYP2C19  polymorphism  is  signiﬁcantly  associated  with
clinical  prognosis  in  coronary  artery  disease  patients  treated
with  clopidogrel.
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